-
-
-
-
-
-
-
Urovant Sciences (UROV) Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board
-
-
-
-
-
-
-
MERGER ALERT – HDS, and UROV: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
-
-
-
-
-
-
-
Urovant Sciences (UROV) Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares
-
-
-
-
-
-
-
Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
-
-
-
-
-
-
-
Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
-
-
-
-
-
-
-
Urovant Sciences (UROV) Appoints James Robinson as President and CEO
-
-
-
-
-
-
-
Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO-902 Gene Therapy in Patients with Overactive Bladder
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

